Answers are grounded in this paper and cite their sources.
Rare steviol glycosides (SGs), characterized by superior sensory profiles and promising bioactivities, are high-intensity sweeteners derived from Stevia rebaudiana. Their intrinsically low abundance limits extraction yields, while in vitro bioconversion is limited by the availability of UDP-glucose (UDPG). Here, an Escherichia coli chassis was reprogrammed to achieve an intracellular UDPG content of 11.72 μmol/g CDW, 2.19-fold that of BL21(DE3), by enhancing pyrimidine nucleotide synthesis, blocking competing pathways, redirecting carbon flux, and optimizing the expression of key genes. Coupled with a UGT−SuSy system, the platform enabled in vitro conversion of Reb A into rare derivativesReb L2, Reb D, Reb D2, Reb M, Reb M2, and Reb M8without exogenous UDPG, with 1.6- to 129-fold higher conversion efficiencies than the wild type. Cultured in a 5 L bioreactor, harvested cells yielded 108.57 g/L Reb L2 and 111.99 g/L Reb D via in vitro whole-cell biotransformation. This platform provides a route for rare SG production and a versatile foundation for the glycodiversification of natural products.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: